Answers are grounded in this paper and cite their sources.
Our findings support that pharmacogene variants influence transplant outcomes. Notable associations include survival related to ABCB1 and ABCC2 variants, tumor occurrence linked to CYP2B6 rs3745274, and renal function affected by multiple pharmacogenes. Variants in CYP2C19 and SLCO1B1 significantly impacted tacrolimus pharmacokinetics and nephrotoxicity risk. These results underline the importance of pharmacogenetic testing for personalized management in kidney transplantation, although further validation in larger cohorts is necessary.
No takes yet. Share an insight, caveat, or question.
Sendra et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: